Dr. Tristan Maurer to Discuss Translational Modeling in Support of Drug Discovery in Rosa’s World-Wide Webinar Series, “Impact of Modeling & Simulation in Drug Development”

Rosa & Co. LLC today announced that Dr. Tristan Maurer, Pfizer Inc., will present a webinar “Translational Modeling & Simulation in Support of Rational Drug Discovery: Principles, Challenges, and Examples” on Tuesday, December 13, 2011 at 1:00 to 2:00 pm EST as part of Rosa’s ongoing monthly public webinar series. The purpose of the series, “Impact of Modeling & Simulation in Drug Development”, is to foster the use of Modeling and Simulation (M&S) activities in biotechnology, pharmaceutics, and other life science industries. This series is geared to illustrate the advantages and applicability of M&S in product discovery, development, and marketing programs. Dr. Maurer’s talk, “Translational Modeling & Simulation in Support of Rational Drug Discovery: Principles, Challenges, and Examples”, will focus on the use of modeling and simulation in support of drug discovery.
“One of the most serious threats to sustained pharmaceutical innovation is the rapidly rising cost of research and development experienced over the past several decades. This exponential rise in cost has been attributed to a variety of factors including increasing technology investments, rising regulatory and commercial hurdles, and higher attrition rates. Among these factors, attrition due to insufficient efficacy and / or safety stands out as a major contributor. Historically high rates of efficacy and safety related attrition suggest that that there is often insufficient knowledge upon which critical decisions in drug discovery are made, namely: which biochemical targets to pursue and which chemical matter to bring forward into the clinic. Preclinical modeling and simulation (e.g. systems biology, PK/PD) is a useful approach to integrating biological information toward the selection of the most promising targets and the design of the most promising chemical matter. As such, over the past several years, quantitative modeling and simulation has become increasingly popular among pharmaceutical companies seeking to reduce attrition. This presentation will provide the rationale for quantitative modeling and simulation, guiding principles for successful implementation of fit for purpose models, and examples illustrative of value added in drug discovery.”

Register for this free webinar at www.rosaandco.com/webinar. After registering, a confirmation email will be sent with directions for joining the webinar. More information about the webinar series, an archive of past webinars, and a list of future webinar speakers may be found at www.rosaandco.com/webinar.

Rosa informs our customer’s most critical decisions – from preclinical through clinical development – with the creation and use of mathematical models that simulate disease physiology, drug action, patient variability, and trial outcomes. To address the full spectrum of related issues, Rosa offers two customized approaches: classic pharmacokinetic/pharmacodynamic (PK/PD) models and Rosa’s innovative PhysioPD™ models. With these approaches, Rosa’s clients collaborate in model creation and testing, retain the final model, and acquire the ability to use it and understand its implications for their drug development programs. Rosa’s staff have close to two decades of unparalleled professional experience in using drug-disease modeling and simulation (M&S) to accelerate drug development; they have covered hundreds of applications with dozens of clients. The Rosa team is unique in their breadth and depth of disease area experience, which includes metabolic and cardiovascular diseases, oncology, gastro-intestinal disease, inflammatory diseases, immune dysfunction (including rheumatoid arthritis), pain, skin conditions, respiratory disorders, and antibacterials/antivirals. For more information, visit www.rosaandco.com.

751 Laurel St., Ste. 127,
San Carlos, CA 94070

This release was published on openPR.